Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NasdaqGS - Nasdaq Real Time Price USD

Vir Biotechnology, Inc. (VIR)

Compare

6.48

+0.30

+(4.85%)

At close: April 2 at 4:00:00 PM EDT

6.16

-0.32

(-4.98%)

After hours: April 2 at 7:39:37 PM EDT

Vir Biotechnology, Inc. (NASDAQ:VIR) is favoured by institutional owners who hold 53% of the company

Key Insights Given the large stake in the stock by institutions, Vir Biotechnology's stock price might be vulnerable to...

Simply Wall St. 5 days ago

VIR
+4.85%
Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta

SAN FRANCISCO, March 13, 2025--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first patient in its Phase 3 ECLIPSE registrational program. The ECLIPSE registrational program is designed to evaluate the efficacy and safety of tobevibart in combination with elebsiran in people living with chronic hepatitis delta (CHD). ECLIPSE 1, the first trial of the program to be initiated, and ECLIPSE 2 are Phase 3 trials designed to provide the registrational data needed for submi

Business Wire 20 days ago

VIR
+4.85%
Analysts Have Lowered Expectations For Vir Biotechnology, Inc. (NASDAQ:VIR) After Its Latest Results

Vir Biotechnology, Inc. ( NASDAQ:VIR ) defied analyst predictions to release its annual results, which were ahead of...

Simply Wall St. last month

VIR
+4.85%
Q4 2024 Vir Biotechnology Inc Earnings Call

Q4 2024 Vir Biotechnology Inc Earnings Call

Thomson Reuters StreetEvents last month

VIR
+4.85%
SNY

ALNY
Vir Biotechnology Inc (VIR) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...

Vir Biotechnology Inc (VIR) showcases progress in oncology and infectious disease programs while managing financial hurdles and operational restructuring.

GuruFocus.com last month

VIR
+4.85%
Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Lags Revenue Estimates

Vir Biotechnology (VIR) delivered earnings and revenue surprises of 10.59% and 15.22%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

VIR
+4.85%
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

SAN FRANCISCO, February 26, 2025--Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2024.

Business Wire last month

VIR
+4.85%
Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference

SAN FRANCISCO, February 19, 2025--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that members of the executive team are scheduled to participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4 at 8:50 a.m. PT / 11:50 a.m. ET in Boston, Massachusetts.

Business Wire last month

VIR
+4.85%
Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

SAN FRANCISCO, February 12, 2025--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that the Company will provide a corporate update and report financial results for the fourth quarter and full year ended December 31, 2024, on February 26, 2025. The Company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on February 26, 2025.

Business Wire last month

VIR
+4.85%
Why Vir Biotechnology, Inc. (VIR) Is Skyrocketing Now

We recently compiled a list of the Why These 15 Stocks Are Skyrocketing in 2025. In this article, we are going to take a look at where Vir Biotechnology, Inc. (NASDAQ:VIR) stands against the other stocks that are skyrocketing now. The market has started to favor smaller companies in 2025, and stocks between $1 billion and […]

Insider Monkey 2 months ago

VIR
+4.85%
Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why

On Wednesday, Vir Biotechnology, Inc. (NASDAQ:VIR) presented initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, which targets a variety of HER2-expressing solid tumors, and VIR-5500, which targets PSMA in metastatic castration-resistant prostate cancer (mCRPC). Data show encouraging preliminary safety and efficacy profiles with no dose-limiting cytokine release syndrome, maximum tolerated dose not yet reached as dose escalation continues, and early clinical respon

Benzinga 2 months ago

VIR
+4.85%
VIR Stock Up on Early Safety & Efficacy Data on Two Cancer Candidates

Vir Biotechnology posts encouraging initial data from phase I studies evaluating VIR-5818 and VIR-5500 in heavily pretreated patients with various solid tumors.

Zacks 2 months ago

VIR
+4.85%
Vir Biotechnology Reports Promising Trial Results for Cancer Therapies

Vir Biotechnology ( (VIR) ) has issued an update. Vir Biotechnology announced promising Phase 1 trial results for its dual-masked T-cell engagers, VIR-5818 and VIR-5500, targeting HER2-expressing solid tumors and PSMA in metastatic castration-resistant prostate cancer respectively. The data showed compelling early clinical responses and a favorable safety profile, with no dose-limiting toxicities and no severe cytokine release syndrome observed. The findings support the potential of Vir’s PRO-XT

TipRanks 2 months ago

VIR
+4.85%
Vir Biotechnology Catapults 58% On Promising Results In Cancer Treatment

Vir Biotechnology announced promising results Wednesday for a pair of cancer treatments, and Vir stock catapulted by double digits.

Investor's Business Daily 2 months ago

VIR
+4.85%
Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC

SAN FRANCISCO, January 08, 2025--Vir Biotechnology, Inc. (Nasdaq: VIR) today is presenting initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, targeting a variety of HER2-expressing solid tumors; and VIR-5500, targeting PSMA in metastatic castration-resistant prostate cancer (mCRPC). Data show encouraging preliminary safety and efficacy profiles with no dose-limiting cytokine release syndrome (CRS), maximum tolerated dose (MTD) not yet reached as dose escalation co

Business Wire 2 months ago

VIR
+4.85%
Vir Biotechnology price target lowered to $14 from $15 at BofA

BofA lowered the firm’s price target on Vir Biotechnology (VIR) to $14 from $15 and keeps a Neutral rating on the shares. While political and rate uncertainty continues to be an overhang, the firm views the health of the Biopharma sector as “markedly improved from 2022 lows.” For stocks in its coverage, the firm continues to like late-stage clinical or early launch stories, although it sees Phase 1 clinical programs with derisking data and near-term catalysts as “increasingly areas of investor f

TipRanks 2 months ago

VIR
+4.85%
Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SAN FRANCISCO, December 18, 2024--Vir Biotechnology Inc. (NASDAQ: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, at 4:30 p.m. PT in San Francisco, California.

Business Wire 3 months ago

VIR
+4.85%
Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta

SAN FRANCISCO, December 12, 2024--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that tobevibart and elebsiran have received U.S. Food and Drug Administration (FDA) Breakthrough Therapy designation and European Medicines Agency (EMA) Priority Medicines (PRIME) designation for the treatment of chronic hepatitis delta (CHD). The designations are supported by compelling positive safety and efficacy data from the Phase 2 SOLSTICE trial, from which the Company recently presented new data at AA

Business Wire 3 months ago

VIR
+4.85%
Janux Catapults 49% On 'Unprecedented' Results In Prostate Cancer; Vir Goes For A Ride

Shares of Janux Therapeutics skyrocketed Tuesday on "unprecedented" results for an experimental prostate cancer treatment.

Investor's Business Daily 3 months ago

JANX

VIR
+4.85%
Will Vir Biotechnology (NASDAQ:VIR) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Simply Wall St. 3 months ago

VIR
+4.85%

Performance Overview

Return	VIR	S&P 500 (^GSPC)
YTD	-11.72%	-3.58%
1-Year	-32.64%	+8.94%
3-Year	-74.39%	+24.75%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Vir Biotechnology, Inc. (VIR)

Vir Biotechnology, Inc. (NASDAQ:VIR) is favoured by institutional owners who hold 53% of the company

Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta

Analysts Have Lowered Expectations For Vir Biotechnology, Inc. (NASDAQ:VIR) After Its Latest Results

Q4 2024 Vir Biotechnology Inc Earnings Call

Vir Biotechnology Inc (VIR) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...

Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Lags Revenue Estimates

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference

Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

Why Vir Biotechnology, Inc. (VIR) Is Skyrocketing Now

Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why

VIR Stock Up on Early Safety & Efficacy Data on Two Cancer Candidates

Vir Biotechnology Reports Promising Trial Results for Cancer Therapies

Vir Biotechnology Catapults 58% On Promising Results In Cancer Treatment

Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC

Vir Biotechnology price target lowered to $14 from $15 at BofA

Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta

Janux Catapults 49% On 'Unprecedented' Results In Prostate Cancer; Vir Goes For A Ride

Will Vir Biotechnology (NASDAQ:VIR) Spend Its Cash Wisely?

Performance Overview